Tenascin‐W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients

Tenascins are extracellular matrix proteins present during the development of organisms as well as in pathological conditions. Tenascin‐W, the fourth and last member of the tenascin family remains the least well‐characterized one. Our study aimed to evaluate the potential significance of tenascin‐W as cancer biomarker by monitoring its presence in the serum of colorectal and breast cancer patients and its expression in colorectal tumor tissues. To measure serum tenascin‐W levels, a sensitive sandwich‐ELISA was established. Mean tenascin‐W concentration in sera of patients with nonmetastatic colorectal cancer at time of diagnosis was highly increased compared to that of healthy volunteers. A similar tendency was observed for tenascin‐C in the same patient cohort. However, the increase was much more striking for tenascin‐W. We also detected elevated tenascin‐W levels in sera of breast cancer patients. Furthermore, we could show a prominent expression of tenascin‐W in extracts from colorectal tumor tissues by immunoblot analysis, whereas tenascin‐W was not detectable in the corresponding normal colon mucosa. To confirm the western blot results, we performed immunohistochemistry of frozen sections of the same patients as well as of an additional, independently chosen collection of colorectal cancer tissues. In all cases, similarly to tenascin‐C, tenascin‐W was detected in the tumor stroma. Our results reveal a clear association between elevated levels of tenascin‐W and the presence of cancer. These results warrant further studies to evaluate the potential value of serum and tissue tenascin‐W levels as diagnostic, prognostic or monitoring biomarker in colorectal, breast and possibly other solid cancers. © 2008 Wiley‐Liss, Inc.

[1]  G. Toda,et al.  Serum tenascin levels in chronic liver disease. , 2008, Liver.

[2]  C. Ruiz,et al.  Tenascin-W is a novel marker for activated tumor stroma in low-grade human breast cancer and influences cell behavior. , 2007, Cancer research.

[3]  G. Rennert,et al.  Detecting K-ras mutations in stool from fecal occult blood test cards in multiphasic screening for colorectal cancer. , 2007, Cancer letters.

[4]  M. Hegi,et al.  Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization. , 2007, Cancer research.

[5]  A. El-Karef,et al.  Expression of large tenascin-C splice variants by hepatic stellate cells/myofibroblasts in chronic hepatitis C. , 2007, Journal of hepatology.

[6]  Y. Okazaki,et al.  Clinical Significance of Large Tenascin-C Spliced Variant as a Potential Biomarker for Colorectal Cancer , 2007, World Journal of Surgery.

[7]  V. Yong,et al.  Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12. , 2006, Cancer research.

[8]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  D. Schuppan,et al.  Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha. , 2006, World journal of gastroenterology.

[10]  R. Tucker,et al.  Avian tenascin‐W: Expression in smooth muscle and bone, and effects on calvarial cell spreading and adhesion in vitro , 2006, Developmental dynamics : an official publication of the American Association of Anatomists.

[11]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[12]  A. El-Karef,et al.  Circulating level of large splice variants of tenascin‐C is a marker of piecemeal necrosis activity in patients with chronic hepatitis C , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[13]  P. Rutgeerts,et al.  The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases , 2005, Nature Clinical Practice Gastroenterology &Hepatology.

[14]  M. Toepler,et al.  Pyruvatkinase M2 (Tumor M2-PK) im Stuhl als Screeningparameter für kolorektale Neoplasien. Eine Übersicht über bisher publizierte Daten , 2005 .

[15]  L. Frati,et al.  Tenascin C and epidermal growth factor receptor as markers of circulating tumoral cells in bladder and colon cancer. , 2005, Oncology reports.

[16]  E. Cukierman,et al.  Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression. , 2005, Seminars in cancer biology.

[17]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[18]  G. Orend.  Potential oncogenic action of tenascin-C in tumorigenesis. , 2005, The international journal of biochemistry & cell biology.

[19]  A. Scherberich,et al.  Tenascin-W is found in malignant mammary tumors, promotes alpha8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-alpha induced expression in vitro , 2005, Oncogene.

[20]  H. Moses,et al.  Tumor-stroma interactions. , 2005, Current opinion in genetics & development.

[21]  J. Schwarzbauer,et al.  Coregulation of fibronectin signaling and matrix contraction by tenascin-C and syndecan-4. , 2004, Molecular biology of the cell.

[22]  N. Fusenig,et al.  Friends or foes — bipolar effects of the tumour stroma in cancer , 2004, Nature Reviews Cancer.

[23]  E. Oakeley,et al.  Differential Gene Expression Analysis Reveals Activation of Growth Promoting Signaling Pathways by Tenascin-C , 2004, Cancer Research.

[24]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[25]  A. Scherberich,et al.  Murine tenascin-W: a novel mammalian tenascin expressed in kidney and at sites of bone and smooth muscle development , 2004, Journal of Cell Science.

[26]  J. Schneider,et al.  Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. , 2003, Anticancer research.

[27]  Matthias Chiquet,et al.  Tenascins: regulation and putative functions during pathological stress , 2003, The Journal of pathology.

[28]  T. Sakakura,et al.  Involvement of large tenascin-C splice variants in breast cancer progression. , 2003, The American journal of pathology.

[29]  P. Hardt,et al.  Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. , 2003, Anticancer research.

[30]  B. Wollenberg,et al.  The significance of Tenascin-C serum level as tumor marker in squamous cell carcinoma of the head and neck. , 2002, Anticancer research.

[31]  N. Hiraiwa,et al.  Tenascin-C expression and splice variant in habu snake venom-induced glomerulonephritis. , 2002, Experimental and molecular pathology.

[32]  Jeffrey C. Allen,et al.  Tenascin-C promotes microvascular cell migration and phosphorylation of focal adhesion kinase. , 2002, Cancer research.

[33]  J. Moyano,et al.  Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. , 2001, Cancer research.

[34]  D. Slamon,et al.  Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. , 2001, The American journal of pathology.

[35]  Mina J. Bissell,et al.  Putting tumours in context , 2001, Nature Reviews Cancer.

[36]  Alan Wells,et al.  Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor , 2001, The Journal of cell biology.

[37]  J. Costa,et al.  Detection of the mutated K-Ras biomarker in colorectal carcinoma. , 2001, Experimental and molecular pathology.

[38]  P. Hardt,et al.  Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. , 2000, Anticancer research.

[39]  G. Schulze.  The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer. , 2000, Anticancer research.

[40]  H. Kosmehl,et al.  Synthesis and protein distribution of the unspliced large tenascin‐C isoform in oral squamous cell carcinoma , 1999, The Journal of pathology.

[41]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[42]  M. Schachner,et al.  Zebrafish tenascin-W, a new member of the tenascin family. , 1998, Journal of neurobiology.

[43]  P. Jones,et al.  Regulation of Tenascin-C, a Vascular Smooth Muscle Cell Survival Factor that Interacts with the αvβ3 Integrin to Promote Epidermal Growth Factor Receptor Phosphorylation and Growth , 1997, The Journal of cell biology.

[44]  J. Volanakis,et al.  C-reactive protein , 1997, Immunologic research.

[45]  A. Shamsuddin,et al.  A simple mucus test for cancer screening. , 1996, Anticancer research.

[46]  G. Vollmer,et al.  Tenascin‐C in serum: A questionable tumor marker , 1995, International journal of cancer.

[47]  P. Schlag,et al.  Significance of tenascin serum level as tumor marker in primary colorectal carcinoma , 1995, International journal of cancer.

[48]  G. Vollmer,et al.  Tenascin‐C in serum: an acute‐phase protein or a carcinoma marker? , 1995, International journal of cancer.

[49]  K. Kato,et al.  Development and application of an enzyme immunoassay for tenascin. , 1993, Clinica chimica acta; international journal of clinical chemistry.

[50]  L. Zardi,et al.  Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues , 1992, International journal of cancer.

[51]  R. Tucker,et al.  Tenascin in bone morphogenesis: expression by osteoblasts and cell type-specific expression of splice variants. , 1992, Journal of cell science.

[52]  D. Guerry,et al.  Characterization of tenascin secreted by human melanoma cells. , 1991, Cancer research.

[53]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[54]  Shigeki,et al.  Tenascin: cDNA cloning and induction by TGF‐beta. , 1988, The EMBO journal.

[55]  R. Chiquet‐Ehrismann,et al.  Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis , 1986, Cell.

[56]  G. Rennert.  Prevention and early detection of colorectal cancer--new horizons. , 2007, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[57]  Y. Otani,et al.  Plasma large Tenascin-C spliced variant as a possible biomarker for the prediction of hepatic recurrence in colorectal cancer. , 2007, Surgery.

[58]  Kazuhisa Takahashi,et al.  Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer. , 2005, Anticancer research.

[59]  R. Bretzel,et al.  [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data]. , 2005, Zeitschrift fur Gastroenterologie.

[60]  E. Oakeley,et al.  Growth promoting signaling by tenascin-C [corrected]. , 2004, Cancer research.

[61]  V. Paar,et al.  Quantitative tissue carcinoembryonic antigen (T CEA) assay as a screening test for severe dysplasia in colorectal adenomas. , 1999, Acta medica Austriaca.